07.09.26 -- Why "Steady Evolution" Best Describes AI's Future

This webinar explores how inclusive research can be advanced through community partnership models that improve access, build trust and support stronger enrollment and retention. 

Gene therapy requires early, rigorous safety planning and command of pediatric and biosafety rules. Early committee engagement reduces delays and strengthens high‑stakes trials.

Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.

In this clip, Ryan Keane of Korio explains why legacy RTSM vendors, designed for large pharmaceutical companies, often struggle to serve smaller, fast-moving Sponsors.

Explore how fully managed virtual meeting services support clinical research teams with registration, secure portal access, live facilitation, and post-meeting deliverables handled from start to finish.

Artificial intelligence is reshaping regulatory medical writing by accelerating document development while maintaining compliance and scientific rigor, creating faster, regulator-ready submissions without compromising quality.

In today’s regulatory climate, ongoing discussion about FDA workload, funding constraints, and shifting review priorities have sparked anxiety across the biopharma industry — especially for sponsors preparing for key submissions like INDs or NDAs. At Veristat, our most recent interactions reflect continued responsiveness and constructive engagement from FDA.

Simplify biosafety oversight and accelerate study startup with expert guidance that ensures NIH compliance while protecting researchers, communities, and the environment.